Throat

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
星期二, 六月 7, 2022
Fatigue, American Cancer Society, Leukemia, Toxicity, National Cancer Institute, LBL, Adult, Death, Pediatric Blood & Cancer, Escherichia coli, Pain, Blood, Childhood leukemia, Multimedia, Pseudomonas fluorescens, Allergy, Acute leukemia, Cancer, Leg, Non-Hodgkin lymphoma, Infection, Headache, Food, RTOR, DOI, Pain scale, Bleeding, Acute lymphoblastic leukemia, Fever, Jazz Pharmaceuticals, PDQ, Population, Bone marrow, Regulation of tobacco by the U.S. Food and Drug Administration, ALL, Cancer research, Nausea, Tongue, Hypersensitivity, Tightness, Lymphoma, Trae Crowder, Patient, Fast Track, Throat, Sores, Liver, Nursing, Appetite, FDA, Twitter, Birth, Arm, Safety, Physical Sciences-Oncology Centers, Pancreas, Pharmaceutical industry, Birth control, Vaccine, Dietary supplement, Oil, Hematology

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Do not breastfeed while receiving RYLAZE and for 1 week after the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
星期二, 六月 7, 2022
Fatigue, American Cancer Society, Leukemia, Toxicity, National Cancer Institute, LBL, Adult, Death, Pediatric Blood & Cancer, Escherichia coli, Pain, Blood, Childhood leukemia, Pseudomonas fluorescens, Allergy, Acute leukemia, Cancer, Leg, Non-Hodgkin lymphoma, Infection, Headache, Food, RTOR, DOI, Pain scale, Bleeding, Acute lymphoblastic leukemia, Fever, Jazz Pharmaceuticals, PDQ, Population, Bone marrow, Regulation of tobacco by the U.S. Food and Drug Administration, ALL, Cancer research, Nausea, Tongue, Hypersensitivity, Tightness, Lymphoma, Trae Crowder, Patient, Fast Track, Throat, Sores, Liver, Nursing, Appetite, FDA, Twitter, Birth, Arm, Safety, Physical Sciences-Oncology Centers, Pancreas, Pharmaceutical industry, Birth control, Vaccine, Dietary supplement, Oil, Hematology

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.
  • Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Leukemia & Lymphoma.

Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial

Retrieved on: 
星期一, 五月 30, 2022
Rx, Rash, ED, Allergy, Chest pain, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Private Securities Litigation Reform Act, Food, Tadalafil, Agency, Annual report, Tongue, Blood pressure, Isosorbide dinitrate, Patient, Woman, Science, AMF, NASDAQ, BPH, COVID-19, Social responsibility, Research, FDA, SNY, Throat, SAN, Nitrate, Intellectual property, Form 20-F, Forward-looking statement, EMA, Man, Erectile dysfunction, SEC, AUT, Pharmaceutical industry, Sanofi

The U.S. Food and Drug Administration has informed Sanofi that its planned Actual Use Trial (AUT) to support the Rx-to-OTC switch for Cialis (tadalafil) has been placed on clinical hold due to matters surrounding the protocol design.

Key Points: 
  • The U.S. Food and Drug Administration has informed Sanofi that its planned Actual Use Trial (AUT) to support the Rx-to-OTC switch for Cialis (tadalafil) has been placed on clinical hold due to matters surrounding the protocol design.
  • Sanofi continues to work with FDA to move the Cialis program forward and will engage the Agency in upcoming meetings as we determine next steps.
  • Cialis is the only PDE-5 inhibitor treatment that offers men a choice when it comes to treatment for erectile dysfunction - Cialis for use as needed and Cialis for once daily use.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Breathing Better Starts with Understanding How Asthma and Allergy Are Connected

Retrieved on: 
星期四, 五月 19, 2022
Physician, Inflammation, Seoul National University Bundang Hospital, Population, Conditional sentence, Allergy, Research, Allergen, Allergic rhinitis, International, Journal, EDT, Doctor of Philosophy, Sinusitis, Eosinophilic bronchitis, Article One, Patient, Respiratory system, Chronic cough, Mark (given name), Quality of life, ARIA, Throat, Awareness, World Allergy Organization, Allergist, WAO, Human, Cough, Phlegm, Update, Wheeze, Article, White book, Nose, ABPM, MITES, Mouth, Pharmaceutical industry, Asthma, MD

MILWAUKEE, May 19, 2022 /PRNewswire-PRWeb/ -- World Allergy Organization (WAO) will host World Allergy Week from June 5 to 11, 2022, to raise awareness about how asthma and allergic airway diseases are connected and how important it is for both physicians and patients to understand and manage both.

Key Points: 
  • Research indicates that the percentage of asthma cases reported in patients with allergic rhinitis can be up to 38%.
  • "Fortunately, in many parts of the world, allergists have therapeutic options to help patients manage their asthma and allergies, but it starts with understanding how asthma and airway allergies are connected.
  • EAACI Global Atlas of Asthma 2021 update, European Academy of Allergy Asthma and Clinical Immunology
    Nunes C et al, "Asthma costs and social impact", Asthma Research and Practice 2017, Vol 3, Article 1.
  • WAO White Book on Allergy, Update 2013, World Allergy Organization
    The World Allergy Organization (WAO) is an international alliance of 108 regional and national allergy, asthma and immunology societies.

Asep Medical Holdings Inc. Taking Actions for Revocation of Cease Trade Order

Retrieved on: 
星期三, 五月 11, 2022
COVID-19, Forward-looking statement, Mission statement, ASEP, Mortality, SEC filing, Company, CTO, Physician, NI, Sinusitis, CSE, Certification, Review, Risk, Lung, National instrument, Annual Filing Season Program, Diagnosis, British Columbia Securities Commission, Overalls, Skin, Multimedia, Death, Intention, View, Throat, Solution, News, Sepsis, Annual, Disease, Medicine, BC, Disclosure

As a result, the British Columbia Securities Commission has issued a Cease Trade Order ("CTO") that has temporarily suspended the trading activities of the Company.

Key Points: 
  • As a result, the British Columbia Securities Commission has issued a Cease Trade Order ("CTO") that has temporarily suspended the trading activities of the Company.
  • The CTO will be in effect until the Annual Filings are filed and a revocation order is issued.
  • ABOUT ASEP MEDICAL HOLDINGS INC.
    Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/asep-medical-holdings-inc-takin...
    SOURCE ASEP Medical Holdings Inc.

Penn Medicine Becker ENT & Allergy Opens New South Street Office In Philadelphia, PA

Retrieved on: 
星期一, 五月 2, 2022
Weingut Brüder Dr. Becker, ENT, Allergist, Thomas Jefferson University Hospital, Physician, Audiology, Patient, Becker, Hearing loss, Sleep, Quality of life, Throat, Thyroid, Nose, Health insurance, Allergy, South Street, Walnut Street

PHILADELPHIA, May 2, 2022 /PRNewswire-PRWeb/ -- Penn Medicine Becker ENT and Allergy is pleased to announce the opening of its newest location in Philadelphia, Pennsylvania. In addition to its locations across New Jersey, Penn Medicine Becker ENT and Allergy expands to meet the needs of patients residing in Philadelphia and surrounding areas. Individuals can now receive specialized, high-quality care in Yardley and Philadelphia, Pennsylvania. Expanding upon the practice's Walnut Street office, Becker ENT and Allergy opens the doors of its newest location on South Street. Regardless of a patient's chosen location, Becker ENT and Allergy has an excellent reputation for employing the best physicians and providing a wide range of treatment options to meet all of its patient's complex and unique needs.

Key Points: 
  • Expanding upon the practice's Walnut Street office, Becker ENT and Allergy opens the doors of its newest location on South Street .
  • In congruence with Penn Medicine Becker ENT and Allergy's previous locations, the South Street office delivers cutting-edge ear, nose, and throat (ENT) care.
  • Penn Medicine Becker ENT and Allergy South Street is uniquely positioned to address all ENT and Allergy conditions.
  • Penn Medicine Becker ENT and Allergy is thrilled to begin serving the Philadelphia community with top-notch otolaryngology, allergy, and hearing loss services.

Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.

Retrieved on: 
星期四, 四月 21, 2022
CSE, News, Multiple organ dysfunction syndrome, COVID-19, Depository Trust Company, Risk, U.S. Securities and Exchange Commission, Intention, Diagnosis, DTC, Fever, FICC, ASEP, Death, Patient, Infection, Sepsis, COO, Lung, Throat, Mortality, Review, Founder, Hyperventilation, Company, OTCQB, Skin, Solution, Forward-looking statement, Sinusitis, Disease, Physician, Mission statement, Multimedia, Overalls, Disclosure, Fatigue, Security (finance), Medicine, Pharmaceutical industry, BC

VANCOUVER, BC, April 21, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF)is pleased to announce its recent successful listing on the OTCQB Venture Market in the US.

Key Points: 
  • VANCOUVER, BC, April 21, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF)is pleased to announce its recent successful listing on the OTCQB Venture Market in the US.
  • Asep Inc. will officially commence trading on the OTCQB as of the market opening today.
  • The listing is expected to provide us with added liquidity and a diversified investor base in a large established public market.
  • ABOUT ASEP MEDICAL HOLDINGS INC.
    Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs.

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Retrieved on: 
星期一, 四月 11, 2022
Conclusion, 2D, Squamous cell carcinoma, Head, Trike, CD28, Mouth, HNSCC, Goal, Prostate cancer, GLOBE, FANCA, University, Security (finance), ADCC, Toxicity, Cancer, Radiation, Therapy, NASDAQ, CD16, Immunotherapy, Annual report, Man, Ovarian cancer, Brain, FA, Society, Muscle, Melanoma, CRISPER, Fanconi anemia, NK, Patient, Company, B7, Form 10-K, HPV, Exocrine gland, Tumor microenvironment, Woman, Neoplasm, Incidence, KO, Throat, GT, Flow cytometry, University of Minnesota, Vaccine, Medical imaging, Neck

BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that it is presenting pre-clinical data at the American Association For Cancer Research Annual Meeting 2022. The poster presentation titled, “#3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas,” presented by Dr. Jeff Miller's laboratory, University of Minnesota.

Key Points: 
  • The poster presentation titled, #3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas, presented by Dr. Jeff Miller's laboratory, University of Minnesota.
  • Background - According to the American Society of Clinical Oncologys information hub, head and neck cancers account for about 4% of all cancers in the United States.
  • In 2021, an estimated 66,630 people (48,740 men and 17,890 women) will develop head and neck cancer.
  • For more information about squamous cell carcinomas of the head and neck please click here .

South African Teaching Hospital Achieves CRE Superbug Decrease Following Novel Environmental Hygiene Intervention

Retrieved on: 
星期二, 四月 5, 2022
Education, Health, Infectious Diseases, Hospitals, Surgery, General Health, University, Journal of Hospital Infection, Nephrology, Journal, University, Waste Control Specialists, Gastroenterology, CRE, Adult, Cardiology, Decontamination, University of the Witwatersrand, Urology, Research, Subclinical infection, PMID, Â, Technology, Critical care, Hope, Throat, Solution, Carbapenem-resistant enterobacteriaceae, UV, Patient, Infection, Pharmaceutical industry, Hospital, Medical device

The study results have been published in the March 2022 issue of The Journal of Hospital Infection.

Key Points: 
  • The study results have been published in the March 2022 issue of The Journal of Hospital Infection.
  • The intervention included broad UV room decontamination across five high-risk patient units (including critical care, oncology, transplant and gastrointestinal surgery rooms) during a 12-month period following a 12-month baseline and two-month, wash-in period.
  • For each scenario, the UV device was operated with five-minute treatment cycles, the number of which varied per room setting and size.
  • Wits Donald Gordon Medical Centre (WDGMC) is the first and only private teaching hospital in South Africa.

HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission

Retrieved on: 
星期二, 四月 5, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Hospital, National, ELife, Therapy, Vaccination, Death, SENAI, Infection, Vaccine, Research, Pathology, National Institute, RNA, Immunity, Omicron, National Institute of Allergy and Infectious Diseases, Immune system, Safety, HDT, RNA transfection, Throat, COVID-19, Extrapyramidal system, Animal, Disease

In addition, the animal studies showed that even when not matched against variants, HDT Bios RNA vaccine protects against lower respiratory tract infection and disease regardless of viral strain.

Key Points: 
  • In addition, the animal studies showed that even when not matched against variants, HDT Bios RNA vaccine protects against lower respiratory tract infection and disease regardless of viral strain.
  • The advantage of using a lower dose of RNA not only is improved overall safety, but also enables HDT Bio to deliver multiple RNA molecules in one vaccine targeting multiple variants of the virus.
  • The results showed that HDT Bio vaccines matched to a variant shut down the virus in the upper respiratory tract, which includes nasal passages, throat and windpipe.
  • HDT Bio is conducting clinical trials of its COVID-19 RNA vaccine in the U.S. and internationally with partners in Brazil, South Korea and China.